{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T20:50:42Z","timestamp":1785876642006,"version":"3.56.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T00:00:00Z","timestamp":1755820800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008322","name":"CSL Behring LLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacionline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Allergy and Clinical Immunology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.jaci.2025.08.005","type":"journal-article","created":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T23:18:04Z","timestamp":1756250284000},"page":"1756-1760.e4","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Garadacimab in hereditary angioedema due to normal C1INH with F12\/PLG mutations"],"prefix":"10.1016","volume":"156","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9036-3723","authenticated-orcid":false,"given":"Danny M.","family":"Cohn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avner","family":"Reshef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Staubach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William R.","family":"Lumry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrike","family":"Feuersenger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris","family":"Jacobs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingo","family":"Pragst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce","family":"Zuraw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konrad","family":"Bork","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaci.2025.08.005_bib1","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s13223-021-00537-2","article-title":"Assessment and management of disease burden and quality of life in patients with hereditary angioedema: a consensus report","volume":"17","author":"Bork","year":"2021","journal-title":"Allergy Asthma Clin Immunol"},{"key":"10.1016\/j.jaci.2025.08.005_bib2","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1111\/all.15214","article-title":"The international WAO\/EAACI guideline for the management of hereditary angioedema\u2013the 2021 revision and update","volume":"77","author":"Maurer","year":"2022","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2025.08.005_bib3","doi-asserted-by":"crossref","DOI":"10.1002\/clt2.12243","article-title":"Current challenges and future opportunities in patient-focused management of hereditary angioedema: a narrative review","volume":"13","author":"Grumach","year":"2023","journal-title":"Clin Transl Allergy"},{"key":"10.1016\/j.jaci.2025.08.005_bib4","doi-asserted-by":"crossref","first-page":"447","DOI":"10.2147\/JAA.S398333","article-title":"Managing diagnosis, treatment, and burden of disease in hereditary angioedema patients with normal C1-esterase inhibitor","volume":"16","author":"Jones","year":"2023","journal-title":"J Asthma Allergy"},{"key":"10.1016\/j.jaci.2025.08.005_bib5","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/0091-6749(83)90052-0","article-title":"Kinin formation in hereditary angioedema plasma: evidence against kinin derivation from C2 and in support of \"spontaneous\" formation of bradykinin","volume":"72","author":"Fields","year":"1983","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.08.005_bib6","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/all.15603","article-title":"Chronic spontaneous urticaria: focus on pathophysiology to unlock treatment advances","volume":"78","author":"Kaplan","year":"2023","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2025.08.005_bib7","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.jaip.2020.08.046","article-title":"US HAEA medical advisory board 2020 guidelines for the management of hereditary angioedema","volume":"9","author":"Busse","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2025.08.005_bib8","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.jaci.2024.05.017","article-title":"DAB2IP associates with hereditary angioedema: insights into the role of VEGF signaling in HAE pathophysiology","volume":"154","author":"D'Apolito","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.08.005_bib9","article-title":"Hereditary angioedema with normal C1 inhibitor associated with carboxypeptidase N deficiency","volume":"3","author":"Vincent","year":"2024","journal-title":"J Allergy Clin Immunol Glob"},{"key":"10.1016\/j.jaci.2025.08.005_bib10","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.jaci.2024.03.024","article-title":"Definition, acronyms, nomenclature, and classification of angioedema (DANCE): AAAAI, ACAAI, ACARE, and APAAACI DANCE consensus","volume":"154","author":"Reshef","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.08.005_bib11","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1186\/s13023-020-01570-x","article-title":"Clinical features of genetically characterized types of hereditary angioedema with normal C1 inhibitor: a systematic review of qualitative evidence","volume":"15","author":"Bork","year":"2020","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.jaci.2025.08.005_bib12","doi-asserted-by":"crossref","first-page":"518","DOI":"10.3390\/jcm10030518","article-title":"The role of the plasminogen activation system in angioedema: novel insights on the pathogenesis","volume":"10","author":"Napolitano","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.jaci.2025.08.005_bib13","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2023.1146834","article-title":"Mechanisms involved in hereditary angioedema with normal C1-inhibitor activity","volume":"14","author":"Shamanaev","year":"2023","journal-title":"Front Physiol"},{"key":"10.1016\/j.jaci.2025.08.005_bib14","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s12016-025-09027-4","article-title":"Hereditary angioedema with normal C1 inhibitor: an updated international consensus paper on diagnosis, pathophysiology, and treatment","volume":"68","author":"Zuraw","year":"2025","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.jaci.2025.08.005_bib15","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/S0140-6736(21)02225-X","article-title":"Prophylactic use of an anti-activated factor XII monoclonal antibody, garadacimab, for patients with C1-esterase inhibitor-deficient hereditary angioedema: a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"399","author":"Craig","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.jaci.2025.08.005_bib16","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/S0140-6736(23)00350-1","article-title":"Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention (VANGUARD): a global, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Craig","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.jaci.2025.08.005_bib17","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1111\/all.16351","article-title":"Long-term safety and efficacy of garadacimab for preventing hereditary angioedema attacks: phase 3 open-label extension study","volume":"80","author":"Reshef","year":"2025","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2025.08.005_bib18","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1111\/cea.14568","article-title":"Timing of onset of garadacimab for preventing hereditary angioedema attacks","volume":"54","author":"Staubach","year":"2024","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaci.2025.08.005_bib19","doi-asserted-by":"crossref","first-page":"2816","DOI":"10.1182\/blood.2021012945","article-title":"A mechanism for hereditary angioedema caused by a lysine 311-to-glutamic acid substitution in plasminogen","volume":"139","author":"Dickeson","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2025.08.005_bib20","article-title":"Mutant plasminogen in hereditary angioedema is bypassing FXII\/kallikrein to generate bradykinin","volume":"13","author":"Hintze","year":"2022","journal-title":"Front Physiol"},{"key":"10.1016\/j.jaci.2025.08.005_bib22","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.anai.2021.05.028","article-title":"Effectiveness of lanadelumab in patients with hereditary angioedema with normal C1 inhibitor and FXII mutation","volume":"127","author":"Bouillet","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaci.2025.08.005_bib23","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1502325","article-title":"Lanadelumab for prevention of attacks of non-histaminergic normal C1 inhibitor angioedema: results from the randomized, double-blind CASPIAN Study and CASPIAN open-label extension","volume":"16","author":"Riedl","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaci.2025.08.005_bib24","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.anai.2022.01.014","article-title":"A case of normal C1 esterase inhibitor hereditary angioedema successfully treated with berotralstat","volume":"128","author":"Kelbel","year":"2022","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaci.2025.08.005_bib25","doi-asserted-by":"crossref","first-page":"123","DOI":"10.2147\/JAA.S445893","article-title":"Clinical experience with berotralstat in patients with hereditary angioedema with normal C1-esterase inhibitor: a commented case series","volume":"17","author":"Kanarek","year":"2024","journal-title":"J Asthma Allergy"}],"updated-by":[{"DOI":"10.1016\/j.jaci.2026.02.005","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T00:00:00Z","timestamp":1771632000000}},{"DOI":"10.1016\/j.jaci.2026.02.005","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000}}],"container-title":["Journal of Allergy and Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674925008863?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674925008863?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,31]],"date-time":"2026-05-31T04:34:24Z","timestamp":1780202064000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091674925008863"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":24,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S0091674925008863"],"URL":"https:\/\/doi.org\/10.1016\/j.jaci.2025.08.005","relation":{},"ISSN":["0091-6749"],"issn-type":[{"value":"0091-6749","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Garadacimab in hereditary angioedema due to normal C1INH with F12\/PLG mutations","name":"articletitle","label":"Article Title"},{"value":"Journal of Allergy and Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaci.2025.08.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology.","name":"copyright","label":"Copyright"}]}}